Skip to main content
Clinical Trials/NCT02604628
NCT02604628
Completed
Not Applicable

Community-acquired Pneumonia: Increasing Protocol Adherence by Antibiotic Stewardship in a Stepped Wedge Cluster- Randomized Trial

UMC Utrecht12 sites in 1 country4,084 target enrollmentNovember 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Community-acquired Pneumonia
Sponsor
UMC Utrecht
Enrollment
4084
Locations
12
Primary Endpoint
90-day mortality
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to determine the effect of a multifaceted antibiotic stewardship intervention on protocol adherence of moderate-severe community-acquired pneumonia.

Detailed Description

The purpose of the study is to show a decrease in broad-spectrum antibiotics with a non-inferiority in 90-day mortality. Hospitals with a pre-intervention protocol adherence of \>70% are excluded from the primary analysis. Primary analysis will be done with a mixed effects model with a random effects for clusters and time. Crude outcomes and outcomes adjusted for potential confounders will be reported. Primary analysis will be tested one-sided for a decrease in mortality. Secondary analysis to test two-sided for mortality will be performed.

Registry
clinicaltrials.gov
Start Date
November 1, 2015
End Date
February 12, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

MJM Bonten

Prof.

UMC Utrecht

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with CAP who get admitted to a non-ICU department are eligible for inclusion.

Exclusion Criteria

  • Patients aged below 18 years
  • Residence in a nursing home or long-term care facility in the last 14 days
  • Patients hospitalized in an acute care hospital for two or more days in the last 14 days
  • Patients with a history of Cystic Fibrosis
  • Patients with immunodeficiency, defined as having one or more of the following criteria:
  • HIV infection with a last CD4 count of \<300//μL
  • Cytotoxic chemotherapy or radiotherapy in the previous 3 months
  • Chronic hemodialysis \> 3 months
  • History of receiving an organ or bone marrow transplant
  • Using immunosuppressive therapy, include corticosteroid treatment only when dosage is high (\>0,5mg/kg/day) for a longer period of time (\>14 days)

Outcomes

Primary Outcomes

90-day mortality

Time Frame: 90-days after hospital admission

All-cause mortality on day 90 from admission will be assessed from the municipal personal records database

Broad-spectrum antibiotic use

Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week

Antibiotic use will be registered during hospital stay

Secondary Outcomes

  • Clostridium difficile infections(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Hospital readmissions(Hospital readmissions within 30 days of hospital admission will be registered)
  • Antibiotic switches(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • 30-day mortality(30-days after hospital admission)
  • Length of hospital stay(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Length of intravenous antibiotic treatment(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Complications(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Intensive Care admissions(Participants will be followed for the duration of hospital stay, an expected average of 1 week)

Study Sites (12)

Loading locations...

Similar Trials